Citations

Clear

3030 citation(s) found for "Susan, M".

Changing Unit Culture and Fostering Well-being of Staff
Launder, Susan

Mayo Clinic

Global Advances in Health and Medicine | February 5, 2014 | Volume: 3 | Issue: 1_suppl | Pages: No page available

10.7453/gahmj.2014.bpa04 Get It

Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome
Charbonneau, Bridget, Moysich, Kirsten B., Kalli, Kimberly R., Oberg, Ann L. , Vierkant, Robert A. , Fogarty, Zachary C. , Block, Matthew S. , Goergen, Krista M., Cunningham, Julie M. , Rider, David N., Hartmann, Lynn C. , Lawrenson, Kate , Wang, Chen , Song, Honglin , DeFazio, Anna , Johnatty, Sharon E., Phelan, Catherine M., Sellers, Thomas A. , Ramirez, Starr M., Vitonis, Allison F., Terry, Kathryn L. , Pike, Malcolm C. , Wu, Anna H. , Ramus, Susan J. , Diergaarde, Brenda , Shen, Howard C., Jensen, Allan , Menkiszak, Janusz , Lubiński, Jan , Rothstein, Joseph H. , McGuire, Valerie , Sieh, Weiva , Lester, Jenny, Walsh, Christine , Vergote, Ignace , Lambrechts, Sandrina, Despierre, Evelyn, García‐Closas, Montserrat , Brinton, Louise A. , Śpiewankiewicz, Beata, Rzepecka, Iwona K. , Dansonka‐Mieszkowska, Agnieszka , Paddock, Lisa E. , Orlow, Irene , Lundvall, Lene, Olson, Sara H. , Høgdall, Claus , Schwaab, Ira, Harter, Philipp , Flanagan, James M. , Brown, Robert , Ekici, Arif B. , Beckmann, Matthias W. , Hein, Alexander , Eccles, Diana , Lurie, Galina, Hays, Laura E., Bean, Yukie T., Goodman, Marc T. , Campbell, Ian , Fasching, Peter A. , Konecny, Gottfried E. , Kaye, Stanley B., Heitz, Florian , Høgdall, Estrid , Chang‐Claude, Jenny , Kupryjańczyk, Jolanta , Wentzensen, Nicolas , Lambrechts, Diether , Whittemore, Alice S. , Culver, Hoda Anton, Levine, Douglas A. , Kjær, Susanne K. , Menon, Usha , Schildkraut, Joellen M. , Pearce, Celeste Leigh, Rossing, Mary Anne, Chenevix‐Trench, Georgia , group, for the AOCS, ACS, Gayther, Simon A. , Ness, Roberta B., Odunsi, Kunle , Sucheston, Lara E., Knutson, Keith L. , Goode, Ellen L. , Lambrechts, Diether , Maurer, Matthew J. , Fridley, Brooke L. , Preston, Claudia C. , Tyrer, Jonathan P. , Doherty, Jennifer A. , Berg, David Van Den , Berchuck, Andrew , Gentry‐Maharaj, Aleksandra , Cybulski, Cezary , Ziogas, Argyrios , Yang, Hannah , Seibold, Petra , Rudolph, Anja , Bois, Andreas du , Paul, James , Pejovic, Tanja B. , Bandera, Elisa V. , Karlan, Beth Y. , Gronwald, Jacek , Cramer, Daniel W. , group, for the AOCS, ACS, Pharoah, Paul D.P. , Knutson, Keith L. , Fazio, Anna de , Lambrechts, Diether , Kjaer, Susanne K , Ramus, Susan J , Hein, Alexander , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Moysich, Kirsten , Orlow, Irene , Wang, Chen , Campbell, Ian G , Menkiszak, Janusz , Brown, Robert , Fogarty, Zachary C , Flanagan, James M , Heitz, Florian , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , García-Closas, Montserrat , Ekici, Arif B , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Diergaarde, Brenda , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Immunology Research | January 27, 2014 | Volume: 2 | Issue: 4 | Pages: 332-340

10.1158/2326-6066.cir-13-0136 | PMID 24764580 Get It

Abstract The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including 5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous carcinoma cases of European descent across 28 studies from the Ovarian Cancer Association Consortium (OCAC). The strongest associations were found for endometrioid carcinoma and IL2RA SNPs rs11256497 [HR, 1.42; 95% confidence interval (CI), 1.22–1.64; P = 5.7 × 10−6], rs791587 (HR, 1.36; 95% CI, 1.17–1.57; P = 6.2 × 10−5), rs2476491 (HR, = 1.40; 95% CI, 1.19–1.64; P = 5.6 × 10−5), and rs10795763 (HR, 1.35; 95% CI, 1.17–1.57; P = 7.9 × 10−5), and for clear cell carcinoma and CTLA4 SNP rs231775 (HR, 0.67; 95% CI, 0.54–0.82; P = 9.3 × 10−5) after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs seem to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid epithelial ovarian cancer. Cancer Immunol Res; 2(4); 332–40. ©2014 AACR.
Abstract B89: Endogenous hormone levels and lobular involution of the breast among healthy, postmenopausal women in the Komen Tissue Bank Study
Khodr, Zeina G. , Brinton, Louise A. , Patel, Deesha A. , Clare, Susan E. , Visscher, Daniel W., Mies, Carolyn, Storniolo, Anna Maria , Sherman, Mark E. , Pfeiffer, Ruth M. , Gierach, Gretchen L. , Falk, Roni T. , Linville, Laura , Hewitt, Stephen M. , Figueroa, Jonine D.

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: B89-B89

10.1158/1940-6207.prev-12-b89 Get It

Abstract Background: Terminal ductal lobular units (TDLUs), the functional units of the breast for lactation, are the structures from which most breast cancers arise. TDLU involution, reflecting atrophy and loss of TDLUs, has been related to lower subsequent breast cancer risk. The predictors of such breast tissue aging, however, are not well defined. Given that estrogens and other hormones play a central role in the etiology of postmenopausal breast cancers, we conducted a study to assess the relationship between four hormones and sex hormone-binding globulin (SHBG) with markers of TDLU involution. Methods: Subjects included healthy women who volunteered between 2009 and 2011 to participate in the Komen Tissue Bank Study. Participants completed a risk factor questionnaire, provided a blood sample, and donated breast tissue for research. Our analysis was restricted to postmenopausal women who were not currently taking menopausal hormones (n=153). A pathologist, masked to patient data, assessed tissue sections for the presence of TDLUs and, among sections containing TDLUs (n=88), measured TDLU diameters for up to ten TDLUs per section. Both presence of TDLUs and TDLU diameter are inversely related to involution. Chemiluminescent immunometric assays were used to measure serum levels of estradiol (E2), SHBG, follicle-stimulating hormone (FSH), and prolactin. Percent free E2 was calculated from measured E2 and SHBG levels. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the presence of TDLUs (none or any) associated with tertiles of serum hormone and SHBG levels. Multivariable ordinal logistic regression was used to calculate ORs, 95% CIs, and p-trend for TDLU diameter categorized as tertiles (≥218.4, 218.4-281, and ≥281 microns) with serum hormone and SHBG levels. All models were adjusted for potential confounding factors. Results: The study population was 87.6% Caucasian with a mean age of 59.5 years, and >2/3 of the women were overweight or obese. Increasing percent free E2 was significantly associated with larger TDLU diameter (OR>2.53 vs. ≥1.99: 5.58, 95% CI: 1.48-21.07; p-trend=0.01), whereas increasing SHBG was associated with smaller TDLU diameter (OR>73nmol/L vs. ≥38 nmol/L: 0.19, 95% CI: 0.05-0.74; p-trend=0.02). Total E2 (p-trend=0.49), FSH (p-trend=0.85), and prolactin (p-trend=0.58) were not associated with TDLU diameter. We did not find significant relationships between the presence of TDLUs and any of the serum levels. Our observed relationships were not modified by age or other breast cancer risk factors, including BMI, years since menopause, and history of bilateral oophorectomy. Conclusion: Based on limited data, these findings suggest that sex hormones may play a role in TDLU involution. Thus, TDLU involution may represent one mechanism by which hormone levels influence breast cancer risk. TDLU measurements may therefore be helpful in assessing breast cancer risk as a marker of breast tissue aging. Analysis of the relationships between hormones and TDLU involution among premenopausal women may provide additional insights into early events in breast carcinogenesis. Citation Format: Zeina G. Khodr, Mark E. Sherman, Ruth M. Pfeiffer, Gretchen L. Gierach, Louise A. Brinton, Roni T. Falk, Deesha Patel, Laura Linville, Susan E. Clare, Daniel Visscher, Carolyn Mies, Stephen Hewitt, Anna Maria Storniolo, Jonine D. Figueroa. Endogenous hormone levels and lobular involution of the breast among healthy, postmenopausal women in the Komen Tissue Bank Study. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr B89.
Abstract A106: Optimal strategies for selecting samples for sequencing families with a common cancer: The Genetic Epidemiology of Lung Cancer Consortium.
Andrada, Maria de, Gaba, Colette , Mandal, Diptasri , Spitz, Margaret , Anderson, Marshall W., Amos, Christopher I. , Bailey‐Wilson, Joan E. , Pinney, Susan M. , You, Ming

Mayo Clinic

Cancer Prevention Research | January 23, 2014 | Volume: 5 | Issue: 11_Supplement | Pages: A106-A106

10.1158/1940-6207.prev-12-a106 Get It

Abstract In order to select samples that are optimally informative for sequence analysis, studies for the Genetic Epidemiology Consortium, we implemented three strategies for analysis, taking into account the known family histories of lung cancer. Susceptibility for lung cancer arises from a complex interplay between largely unknown genetic factors and smoking behavior. In order to optimize our ability to identify genetic factors for lung cancer we have recruited individuals with extensive family histories of lung cancer and also collected information about their smoking behaviors. For this study, we have modeled family history to identify individuals to select for sequencing using three approaches. First, we used an expert opinion approach in which multiple investigators evaluated pedigree structures with family history to reach a consensus priority in selecting individuals. Second we developed an approximation that assumes a low penetrance among noncarriers and uses known cancer status in first degree relatives. Third, we used the cancer, smoking behaviors and family information along with a likelihood that models penetrance according to genetic susceptibility and an interaction with smoking to estimate the probabilities individuals carry susceptibility factors. In this analysis we compare results among these methods. We evaluate effectiveness of these methods using simulation-based approaches. Citation Format: Christopher Amos, Joan Bailey-Wilson, Susan Pinney, Maria de Andrada, Colette Gaba, Diptasri Mandal, Ming You, Margaret Spitz, Marshall Anderson. Optimal strategies for selecting samples for sequencing families with a common cancer: The Genetic Epidemiology of Lung Cancer Consortium. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A106.
Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Mansfield, Aaron S. , Rabe, Kari G. , Schwager, Susan M., Call, Timothy G. , Brewer, Jerry D., Slager, Susan L. , Shanafelt, Tait D. , Chaffee, Kari G. , Mansfield, Aaron S

Mayo Clinic

Journal of Oncology Practice | January 17, 2014 | Volume: 10 | Issue: 1 | Pages: e1-e4

10.1200/jop.2013.000921 | PMID 23981385 Get It

The authors documented a low compliance with guidelines to screen for skin malignancy in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia.
Shared decision-making as a cost-containment strategy: US physician reactions from a cross-sectional survey
Tilburt, Jon C. , Wynia, Matthew K., Montori, Víctor M. , Egginton, Jason S. , Sheeler, Robert D. , Liebow, Mark , Humeniuk, Katherine M., Goold, Susan Dorr , Thorsteinsdottir, Bjorg , Montori, Victor M

Mayo Clinic

BMJ Open | January 15, 2014 | Volume: 4 | Issue: 1 | Pages: e004027

10.1136/bmjopen-2013-004027 | PMID 24430879 Get It

Objective To assess US physicians’ attitudes towards using shared decision-making (SDM) to achieve cost containment. Design Cross-sectional mailed survey. Setting US medical practice. Participants 3897 physicians were randomly selected from the AMA Physician Masterfile. Of these, 2556 completed the survey. Main outcome measures Level of enthusiasm for “Promoting better conversations with patients as a means of lowering healthcare costs”; degree of agreement with “Decision support tools that show costs would be helpful in my practice” and agreement with “should promoting SDM be legislated to control overall healthcare costs”. Results Of 2556 respondents (response rate (RR) 65%), two-thirds (67%) were ‘very enthusiastic’ about promoting SDM as a means of reducing healthcare costs. Most (70%) agreed decision support tools that show costs would be helpful in their practice, but only 24% agreed with legislating SDM to control costs. Compared with physicians with billing-only compensation, respondents with salary compensation were more likely to strongly agree that decision support tools showing costs would be helpful (OR 1.4; 95% CI 1.1 to 1.7). Primary care physicians (vs surgeons, OR 1.4; 95% CI 1.0 to 1.6) expressed more enthusiasm for SDM being legislated as a means to address healthcare costs. Conclusions Most US physicians express enthusiasm about using SDM to help contain costs. They believe decision support tools that show costs would be useful. Few agree that SDM should be legislated as a means to control healthcare costs.
Purkinje Cell Cytoplasmic Antibody Type 1 (Anti-Yo) Autoimmunity in a Child With Down Syndrome
Philipps, Guillermo, Alisanski, Susan, Pranzatelli, Michael R. , Clardy, Stacey , Lennon, Vanda A. , McKeon, Andrew , Clardy, Stacey L, McKeon, Andrew , Clardy, Stacey L

Mayo Clinic

JAMA Neurology | January 14, 2014 | Volume: 71 | Issue: 3 | Pages: 347

10.1001/jamaneurol.2013.4551 | PMID 24424854 Get It

Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis
Saenger, Amy K., Train, Laura, Kotzer, Katrina E. , Lagerstedt, Susan A., Hornseth, Jean M, Basu, Ananda, Baudhuin, Linnea M. , Donato, Leslie J. , Winters, Jeffrey L.

Mayo Clinic

Journal of Clinical Apheresis | January 13, 2014 | Volume: 29 | Issue: 5 | Pages: 256-265

10.1002/jca.21317 | PMID 24420163 Get It

PD-L1 Expression in Triple-Negative Breast Cancer
Qiao, Na , Wu, Yun , Harrington, Susan M. , Akçakanat, Argun , Curran, Michael A. , Hwu, Patrick , Sharma, Padmanee , Alatrash, Gheath , Mittendorf, Elizabeth A, Mittendorf, EA , Philips, Anne V. , Meric‐Bernstam, Funda , Su, Xiaoping , Wang, Ying , González-Angulo, Ana M. , Chawla, Akhil , Hwu, Patrick , Litton, Jennifer K. , Molldrem, Jeffrey J. , Curran, Michael A , Al-Atrash, Gheath

Mayo Clinic

Cancer Immunology Research | January 10, 2014 | Volume: 2 | Issue: 4 | Pages: 361-370

10.1158/2326-6066.cir-13-0127 | PMID 24764583 Get It

Abstract Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1 (PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine whether PD-L1 is overexpressed in triple-negative breast cancer (TNBC) and to investigate the loss of PTEN as a mechanism of PD-L1 regulation. The Cancer Genome Atlas (TCGA) RNA sequencing data showed significantly greater expression of the PD-L1 gene in TNBC (n = 120) compared with non-TNBC (n = 716; P < 0.001). Breast tumor tissue microarrays were evaluated for PD-L1 expression, which was present in 19% (20 of 105) of TNBC specimens. PD-L1+ tumors had greater CD8+ T-cell infiltrate than PD-L1− tumors (688 cells/mm vs. 263 cells/mm; P < 0.0001). To determine the effect of PTEN loss on PD-L1 expression, stable cell lines were generated using PTEN short hairpin RNA (shRNA). PTEN knockdown led to significantly higher cell-surface PD-L1 expression and PD-L1 transcripts, suggesting transcriptional regulation. Moreover, phosphoinositide 3-kinase (PI3K) pathway inhibition using the AKT inhibitor MK-2206 or rapamycin resulted in decreased PD-L1 expression, further linking PTEN and PI3K signaling to PD-L1 regulation. Coculture experiments were performed to determine the functional effect of altered PD-L1 expression. Increased PD-L1 cell surface expression by tumor cells induced by PTEN loss led to decreased T-cell proliferation and increased apoptosis. PD-L1 is expressed in 20% of TNBCs, suggesting PD-L1 as a therapeutic target in TNBCs. Because PTEN loss is one mechanism regulating PD-L1 expression, agents targeting the PI3K pathway may increase the antitumor adaptive immune responses. Cancer Immunol Res; 2(4); 361–70. ©2014 AACR.
Thyroid Hormone-Responsive Pituitary Hyperplasia Independent of Somatostatin Receptor 2
Brinkmeier, Michelle L. , Stahl, Justin H., Gordon, David F. , Ross, Brian D. , Sarapura, Virginia D. , Dowding, Janet M., Lloyd, Ricardo V., Ridgway, E. Chester, Camper, Sally A. , Kendall, Susan K.

Mayo Clinic

Molecular Endocrinology | January 8, 2014 | Volume: 15 | Issue: 12 | Pages: 2129-2136

10.1210/mend.15.12.0744 | PMID 11731614 Get It

AbstractMice homozygous for the targeted disruption of the glycoprotein hormone α-subunit (αGsu) display hypertrophy and hyperplasia of the anterior pituitary thyrotropes. Thyrotrope hyperplasia results in tumors in aged αGsu−/− mice. These adenomatous pituitaries can grow independently as intrascapular transplants in hypothyroid mice, suggesting that they have progressed beyond simple hyperplasia. We used magnetic resonance imaging to follow the growth and regression of thyrotrope adenomatous hyperplasia in response to thyroid hormone treatment and discovered that the tumors retain thyroid hormone responsiveness. Somatostatin (SMST) and its diverse receptors have been implicated in cell proliferation and tumorigenesis. To test the involvement of SMST receptor 2 (SMSTR2) in pituitary tumor progression and thyroid hormone responsiveness in αGsu−/− mutants, we generated Smstr2−/−, αGsu−/− mice. Smstr2−/−, αGsu−/− mice develop hyperplasia of thyrotropes, similar to αGsu−/− mutants, demonstrating that SMSTR2 is dispensable for the development of pituitary adenomatous hyperplasia. Thyrotrope hyperplasia in Smstr2−/−, αGsu−/− mice regresses in response to T4 treatment, suggesting that SMSTR2 is not required in the T4 feedback loop regulating TSH secretion.